TREMFYA在3年多的时间里对大多数高血压结肠炎病人保持了恢复治疗,没有新的安全问题。 TREMFYA maintained remission in most ulcerative colitis patients over 3 years with no new safety issues.

约翰逊和约翰逊公司报告说,TREMFYA (guselkumab) 在中度至重度性结肠炎的成年人中维持了临床,内镜和组织学改善,直到第140周 (3年),临床缓解率为80. 8%,内镜粘膜改善率为78. 6%,内镜缓解率为53. 6%. Johnson & Johnson reported that TREMFYA (guselkumab) maintained clinical, endoscopic, and histologic improvements in adults with moderate to severe ulcerative colitis through Week 140 (3 years), with 80.8% in clinical remission, 78.6% achieving histo-endoscopic mucosal improvement, and 53.6% in endoscopic remission. 几乎所有缓解患者至少没有使用皮质类固醇8周,而87. 5%的患者在第44周后仍然缓解. Nearly all remission patients were corticosteroid-free for at least eight weeks, and 87.5% remained in remission from Week 44. 约89%的合格参与者完成了治疗,没有新的安全顾虑。 About 89% of eligible participants completed the treatment, with no new safety concerns. 这些数据在ECCO 2026上与有关IBD新疗法的顶级摘要一起进行了介绍,包括儿童克罗恩病中的icotrokinra和STELARA. The data were presented at ECCO 2026, alongside top-tier abstracts on new IBD treatments, including icotrokinra and STELARA in pediatric Crohn’s disease.